<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Metabolomics</journal-id><journal-id journal-id-type="iso-abbrev">Metabolomics</journal-id><journal-title-group><journal-title>Metabolomics</journal-title></journal-title-group><issn pub-type="ppub">1573-3882</issn><issn pub-type="epub">1573-3890</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39920379</article-id><article-id pub-id-type="pmc">PMC11805833</article-id>
<article-id pub-id-type="publisher-id">2217</article-id><article-id pub-id-type="doi">10.1007/s11306-024-02217-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Unveiling the metabolomic profile of growth hormone deficiency children using NMR spectroscopy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aggelaki</surname><given-names>Eftychia A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giannakopoulos</surname><given-names>Aristeidis</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Georgiopoulou</surname><given-names>Panagiota D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chasapi</surname><given-names>Styliani A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Efthymiadou</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kritikou</surname><given-names>Dimitra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chrysis</surname><given-names>Dionisios</given-names></name><address><email>dchrysis@upatras.gr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Spyroulias</surname><given-names>Georgios A.</given-names></name><address><email>G.A.Spyroulias@upatras.gr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017wvtq80</institution-id><institution-id institution-id-type="GRID">grid.11047.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0576 5395</institution-id><institution>Department of Pharmacy, School of Health Sciences, </institution><institution>University of Patras, </institution></institution-wrap>26504 Rio, Greece </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017wvtq80</institution-id><institution-id institution-id-type="GRID">grid.11047.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0576 5395</institution-id><institution>Division of Endocrinology Department of Pediatrics, Medical School, </institution><institution>University of Patras, </institution></institution-wrap>26504 Rio, Greece </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>21</volume><issue>1</issue><elocation-id>25</elocation-id><history><date date-type="received"><day>25</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">The diagnosis of Growth Hormone Deficiency (GHD) during childhood has been the subject of much controversy over the last few years. Aiming to accurate medical treatment, there is a need for biomarker discovery.</p></sec><sec><title>Objective</title><p id="Par2">To characterize the metabolic profile of GHD children, examine the effect of GH administration on the metabolic signature, and investigate the correlations between metabolites and IGF-1.</p></sec><sec><title>Methods</title><p id="Par3">Nuclear Magnetic Resonance (NMR)-based untargeted and targeted metabolomic approach applied to study the metabolic profiles of children with GHD. Plasma, serum, and urine samples were collected from twenty-two children diagnosed with GHD and forty-eight age matched controls from the Pediatric Endocrinology Unit of the University Hospital of Patras. Experimental data were examined by both multivariate and univariate statistical analysis.</p></sec><sec><title>Results</title><p id="Par4">The results of this pilot study revealed a different metabolic fingerprint of children with GHD in comparison to age-matched healthy individuals. However, the detected alterations in the metabolite patterns before and after GH treatment were subtle and of minor discriminative statistical power.</p></sec><sec><title>Conclusions</title><p id="Par5">This study provides evidence that metabolome plays a pivotal role in GHD, but large-scale multicenter studies are warranted to validate the results.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11306-024-02217-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Growth hormone deficiency</kwd><kwd>Metabolomics</kwd><kwd>NMR spectroscopy</kwd><kwd>IGF-1</kwd></kwd-group><funding-group><award-group><funding-source><institution>INSPIRED</institution></funding-source><award-id>MIS 5002550</award-id><award-id>MIS 5002550</award-id><award-id>MIS 5002550</award-id><award-id>MIS 5002550</award-id><principal-award-recipient><name><surname>Aggelaki</surname><given-names>Eftychia A.</given-names></name><name><surname>Georgiopoulou</surname><given-names>Panagiota D.</given-names></name><name><surname>Chasapi</surname><given-names>Styliani A.</given-names></name><name><surname>Spyroulias</surname><given-names>Georgios A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>OMIC-ENGINE</institution></funding-source><award-id>5002636</award-id><award-id>5002636</award-id><principal-award-recipient><name><surname>Georgiopoulou</surname><given-names>Panagiota D.</given-names></name><name><surname>Spyroulias</surname><given-names>Georgios A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>ESPERANCE</institution></funding-source><award-id>101087215</award-id><award-id>101087215</award-id><principal-award-recipient><name><surname>Chasapi</surname><given-names>Styliani A.</given-names></name><name><surname>Spyroulias</surname><given-names>Georgios A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>EU FP7 REGPOT CT-2011-285950&#x0201c;SEE-DRUG&#x0201d;</institution></funding-source><award-id>285950</award-id><award-id>285950</award-id><principal-award-recipient><name><surname>Chasapi</surname><given-names>Styliani A.</given-names></name><name><surname>Spyroulias</surname><given-names>Georgios A.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Growth Hormone Deficiency (GHD) is a disorder caused by inadequate synthesis and/or secretion of growth hormone (GH) from the anterior pituitary gland (Badaru &#x00026; Wilson, <xref ref-type="bibr" rid="CR2">2004</xref>). GHD, approximately, affects one in every 4.000 to 10.000 children and includes a group of disorders with various etiologies (Dattani &#x00026; Malhotra, <xref ref-type="bibr" rid="CR10">2019</xref>). Complete GHD may be the result of surgical removal of pituitary gland in the case of a tumor (e.g., craniopharyngioma) or GH gene deletion. Many other causes, affecting the GH gene or other pituitary transcription factors involved in GH secretion may result in partial deficiency, usually defined by the results of GH provocation clinical tests. The most prevalent clinical sign of GHD in children is growth failure, which is translated to short stature or/and slowed growth in height and its therapy involves subcutaneous injections of recombinant human GH (Grimberg et al., <xref ref-type="bibr" rid="CR13">2017</xref>).</p><p id="Par7">The pattern-release of GH is complex and is characterized by secretory bursts, with two thirds of the total daily GH secretion produced at the first episode of slow-wave sleep. Growth Hormone releasing Hormone (GHRH) and somatostatin are the most important hypothalamic peptide hormones, while several factors might alter the regulation of GH, including stress, exercise and nutritional status (Caputo et al., <xref ref-type="bibr" rid="CR6">2021</xref>). GH exerts pleiotropic effects on multiple organs such as muscle, bone and heart and diverse metabolic pathways, either directly or indirectly. GH binds to GHR of cells and stimulates the liver and other tissues to produce insulin-like growth factors (IGFs), especially IGF-1 (Aguiar-Oliveira &#x00026; Bartke, <xref ref-type="bibr" rid="CR1">2019</xref>). The binding of IGF-1 to its receptor, IGF-1R, is followed by activation of a tyrosine-kinase-mediated intracellular signaling pathway, which leads to increased metabolism, anabolism, cellular replication and growth.</p><p id="Par8">Metabolomics, considered one of the most rapidly developing fields of omic-sciences in recent years, is a powerful approach for in-depth understanding of the biological mechanisms of diseases, and may enhance our diagnostic and prognostic potential (Bruzzone et al., <xref ref-type="bibr" rid="CR5">2023</xref>; Chasapi et al., <xref ref-type="bibr" rid="CR7">2022</xref>; Christopoulou et al., <xref ref-type="bibr" rid="CR8">2023</xref>; Georgakopoulou et al., <xref ref-type="bibr" rid="CR11">2020</xref>; Georgiopoulou et al., <xref ref-type="bibr" rid="CR12">2022</xref>; Katsila et al., <xref ref-type="bibr" rid="CR15">2021</xref>; Matzarapi et al., <xref ref-type="bibr" rid="CR18">2022</xref>; Preter &#x00026; Verbeke, <xref ref-type="bibr" rid="CR23">2013</xref>; Vignoli et al., <xref ref-type="bibr" rid="CR30">2022</xref>). It involves the characterization and quantification of small molecules, within biological systems, such as cells, tissues, organs or an entire organism and the differentiation of their levels appearing in cases of pathological situations. Due to the variation of the metabolome throughout an individual&#x02019;s lifespan, which reflects the physiological state, the interpretation of metabolomics data is a challenging task. However, such data remain rich in biological information (Clish, <xref ref-type="bibr" rid="CR9">2015</xref>). Mass spectrometry (MS) and Nuclear Magnetic Resonance (NMR) spectroscopy are considered the leading analytical approaches for revealing the metabolic state of an organism (Markley et al., <xref ref-type="bibr" rid="CR17">2017</xref>). NMR-based analysis of complex biological samples is a non-destructive technique providing sensitivity, repeatability, and demanding limited sample preparation (Markley et al., <xref ref-type="bibr" rid="CR17">2017</xref>).</p><p id="Par9">Recent studies have shown the specific effects of GH on metabolism when GH is over or under-produced. Acromegaly, a disease state with increased secretion of GH, shows a decrease in branched-chain amino acids (BCAAs) which is inversely correlated to serum IGF-1 (Biagetti et al., <xref ref-type="bibr" rid="CR4">2019</xref>). BCAAs promote skeletal muscle growth by their GH induced increased uptake and can also be used as substrate in gluconeogenesis (Neinast et al., <xref ref-type="bibr" rid="CR20">2018</xref>). The metabolic pathways of glycerophospholipid, sphingolipid and linoleic acid seem also to be affected by increased levels of GH (Wang et al., <xref ref-type="bibr" rid="CR31">2020</xref>). On the other hand, studies on GHD patients have shown reduced fatty acids and changes in different amino acids like glutamic acid and cysteine (H&#x000f6;ybye et al., <xref ref-type="bibr" rid="CR14">2014</xref>).</p><p id="Par10">It is known that GH replacement therapy in GHD patients reduces body fat, increases lean muscle mass, and improves the lipid profile by lowering total cholesterol and low-density lipoprotein (LDL) levels (Yang et al., <xref ref-type="bibr" rid="CR34">2023</xref>). However, at the metabolome level, GH therapy induces only modest changes in diverse metabolites, including glutamic acid, cysteine, and oleic acid, with no specific metabolite being strongly correlated to IGF-1 (H&#x000f6;ybye et al., <xref ref-type="bibr" rid="CR14">2014</xref>).</p><p id="Par11">In this study, we attempt to obtain a detailed view on the metabolic fingerprint of children diagnosed with GHD and describe the differences in its profile 3&#x000a0;months after the initiation of therapy with recombinant GH. Plasma, serum, and urine samples of twenty-two GHD children (n&#x02009;=&#x02009;22) were analyzed by performing untargeted Nuclear Magnetic resonance (NMR)-based metabolomic analysis and compared with forty-eight age-matched controls (n&#x02009;=&#x02009;48).</p><p id="Par12">Urine has been demonstrated to be a valuable sample matrix across multiple omics fields, regarding the plethora of extracted biological information and the non-invasive sample's collection. As a biological waste material, urine typically contains low levels of proteins, and higher of metabolites from a variety of small molecule classes, including alkaloids, amino oxides, amino acids, bile acids, biogenic amines, carboxylic acids, cresols, hormones and related compounds, indoles and derivatives, nucleobases and related compounds, vitamins and cofactors, acylcarnitines, cholesteryl esters, and diglycerides. Despite significant advancements in metabolite identification, not all detected features in urine can be confidently annotated. This limitation in reference databases can impede the interpretation of statistical findings. Research has demonstrated that urine composition is not only formed by underlying health conditions or dietary intake, but also by demographic factors. For instance, studies have shown that both gender and age have a statistically significant effect on the urinary metabolome (Th&#x000e9;venot et al., <xref ref-type="bibr" rid="CR29">2015</xref>), emphasizing the complex nature of this biological fluid. Plasma and serum are both derived from the liquid component of blood after the removal of cells. However, they differ in composition and preparation. Plasma is collected from blood treated with anticoagulants, while serum is obtained after the blood has clotted, resulting in the absence of clotting factors. Consequently, plasma and serum exhibit slightly distinct metabolic profiles, due to variations in metabolite stability, composition and the biological processes related to blood coagulation. Hence, we aim to analyze both plasma and serum metabolome since it offers complementary insights into an organism&#x02019;s metabolic status. To our knowledge, this is the first time that the effect of GH administration has been investigated in a subset of patients following untargeted NMR metabolomics analysis using the three biofluids (plasma, serum, and urine).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethics statement</title><p id="Par13">This study was approved by the General University Hospital of Patras human research ethics committee and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></sec><sec id="Sec4"><title>Population selection</title><p id="Par14">Seventy children, twenty-two diagnosed with GHD (10 girls and 12 boys) and forty-eight healthy children (30 girls and 18 boys) were enrolled in this study, after obtaining informed consent from the patients and/or their parents. GH diagnosis was validated based on clinical and laboratory grounds according to consensus guidelines form GH Research society (Society, <xref ref-type="bibr" rid="CR27">2000</xref>). GHD was defined by stimulated GH levels&#x02009;&#x0003c;&#x02009;10&#x000a0;ng/ml in 2 consecutive GH provocation tests. Moreover, to assess the effects of GH therapy over time, follow-up samples were collected from 15 out of 22 GHD children, three months after the commencement of GH administration. Comprehensive baseline characteristics of all participants are given in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of 70 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Healthy controls (n&#x02009;=&#x02009;48)</th><th align="left">GHD group (n&#x02009;=&#x02009;22)</th><th align="left">3&#x000a0;months after initiation of treatment (n&#x02009;=&#x02009;15)</th></tr></thead><tbody><tr><td align="left">Male/female</td><td align="left">18/30</td><td align="left">12/10</td><td align="left">9/6</td></tr><tr><td align="left">Age (years&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">7.75&#x02009;&#x000b1;&#x02009;2.21</td><td align="left">6.94&#x02009;&#x000b1;&#x02009;3.13</td><td align="left">7.21&#x02009;&#x000b1;&#x02009;2.88</td></tr><tr><td align="left">Weight (kg&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">26.58&#x02009;&#x000b1;&#x02009;13</td><td align="left">20.19&#x02009;&#x000b1;&#x02009;8.47</td><td align="left">n/a</td></tr><tr><td align="left">Height (cm&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">121.031&#x02009;&#x000b1;&#x02009;17.89</td><td align="left">109.78&#x02009;&#x000b1;&#x02009;18.72</td><td align="left">n/a</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">17.25&#x02009;&#x000b1;&#x02009;4.12</td><td align="left">16.03&#x02009;&#x000b1;&#x02009;1.79</td><td align="left">n/a</td></tr><tr><td align="left">IGF-1 (SDS&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">n/a</td><td align="left">&#x02212;&#x02009;0.88&#x02009;&#x000b1;&#x02009;1.42</td><td align="left">1.418&#x02009;&#x000b1;&#x02009;1.02</td></tr></tbody></table><table-wrap-foot><p><italic>BMI</italic> body mass index <italic>IGF-1</italic> insulin-like growth factor-1, <italic>SD</italic> standard deviation, <italic>n/a</italic> not available</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Sample collection and preparation</title><p id="Par15">Plasma, serum, and urine samples were collected under fasting conditions, stored and prepared for NMR analysis according to the below-mentioned protocols, with adaptations as described by Bernini et al. (<xref ref-type="bibr" rid="CR3">2011</xref>). Both sample storage and NMR sample preparation were carried out at the Department of Pharmacy, University of Patras.</p><p id="Par16">From each donor, blood plasma and serum samples were withdrawn using BD Vacutainer&#x000ae; K3-EDTA (K3-ethylenediamine tetra-acetate) spray coated tubes and BD Vacutainer&#x000ae; SSTTM. Serum samples were gently mixed by inverting the tube 5 times. Then they were left at room temperature for 30&#x000a0;min and allowed to clot in an upright position. Blood samples were centrifuged at 1500&#x000d7;g for 10&#x000a0;min at room temperature. For each sample, the supernatant was aliquoted in 3 fractions of 600&#x000a0;&#x003bc;L using 2&#x000a0;mL cryovials and stored at &#x02212;&#x02009;80&#x000a0;&#x000b0;C. Urine samples were stored immediately after collection at 40&#x000a0;&#x000b0;C for maximum of 2&#x000a0;h to avoid cell breaking upon ice crystal formation. Urine samples were centrifuged at 2500&#x000d7;g for 5&#x000a0;min at room temperature and the supernatant from each sample was aliquoted in three fractions of 1&#x000a0;mL each and were stored in 2&#x000a0;mL cryovials at &#x02212;&#x02009;80&#x000a0;&#x000b0;C.</p></sec><sec id="Sec6"><title>NMR sample preparation</title><p id="Par17">Before NMR analysis, frozen aliquots were thawed at room temperature. Plasma and serum samples (300&#x000a0;&#x003bc;L) were mixed with 240&#x000a0;&#x003bc;L of sodium phosphate buffer (0.14&#x000a0;M Na<sub>2</sub>HPO<sub>4</sub>, 0.5&#x000a0;mM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 4% NaN<sub>3</sub> in H<sub>2</sub>O,&#x000a0;pH 7.4) and 60&#x000a0;&#x003bc;L D<sub>2</sub>O.Urine samples (540&#x000a0;&#x003bc;L) were mixed with 60&#x000a0;&#x003bc;L of potassium phosphate buffer (1.5&#x000a0;M KH<sub>2</sub>PO<sub>4</sub>, 100% v/v D<sub>2</sub>O, 0.05&#x000a0;mM DSS and 4% NaN<sub>3</sub>, pH&#x02009;=&#x02009;7.4) (Suarez-Diez et al., <xref ref-type="bibr" rid="CR28">2017</xref>). After vortexing, 550&#x000a0;&#x003bc;L of each mixture was transferred into a 5&#x000a0;mm NMR tube (Bruker BioSpin srl).</p></sec><sec id="Sec7"><title>NMR data acquisition</title><p id="Par18">All spectra were recorded at a Bruker Avance III HD 700&#x000a0;MHz spectrometer equipped with a 5&#x000a0;mm cryogenically cooled 5.0&#x000a0;mm 1H/13C/15N/D Z-gradient probe. To reveal all the detectable <sup>1</sup>H signals of metabolites for plasma, serum and urine samples, two one-dimensional (1D) <sup>1</sup>H NMR spectra were acquired using a standard NOESY (NOESYpresat) pulse sequence for water suppression for all the three specimens, while the 1D <sup>1</sup>H CPMG (Carr-Purcell-Meiboom-Gil) pulse sequence with a presaturation routine only for plasma and serum samples. Also, the homonuclear 2D <sup>1</sup>H <italic>J</italic>-resolved (<italic>J</italic>-res) correlation NMR experiment with presaturation routine, typical for metabolomics experiments, acquired for each sample. More specifically, plasma and serum NMR spectra were acquired at 37&#x000a0;&#x000b0;C, while urine samples at 25&#x000a0;&#x000b0;C. All the acquisition parameters for the 1D <sup>1</sup>H NOESY (noesygppr1d; Bruker), the 1D <sup>1</sup>H CPMG (cpmgpr1d; Bruker), and the 2D <sup>1</sup>H <italic>J</italic>-res (jresgpprqf; Bruker) experiments were identical to those applied in the study of Matzarapi et al. (<xref ref-type="bibr" rid="CR18">2022</xref>).</p></sec><sec id="Sec8"><title>Data processing</title><p id="Par19">All NMR spectra were manually processed using Topspin software (version 4.1.1, Bruker Biospin srl), transforming them appropriately for the subsequent steps of the metabolomic analysis. Specifically, calibration, phase and baseline corrections were performed (Puchades-Carrasco et al., <xref ref-type="bibr" rid="CR24">2016</xref>). Plasma and serum NMR spectra were calibrated on the anomeric proton of a-D-glucose at 5.24&#x000a0;ppm, (d), (considered as an inherent internal standard), while for the urine NMR spectra were aligned on the DSS at 0.00&#x000a0;ppm, (s) (Pearce et al., <xref ref-type="bibr" rid="CR22">2008</xref>). The NMR spectral data were converted into a data matrix (bucket table) using Amix 3.9.12 software (Bruker BioSpin) following the &#x0201c;bucketing&#x0201d; method. Blood plasma and serum 1D <sup>1</sup>H CPMG spectra were segmented into buckets of 0.04&#x000a0;ppm width in the spectral region from 0.7 to 8.85&#x000a0;ppm. <sup>1</sup>H signals of water (4.68&#x02013;5.10&#x000a0;ppm) were excluded from the plasma and serum bucket table. Also, the resonances of the anticoagulant ethylenediamine tetra-acetate (EDTA) (2.55&#x02013;2.62, 2.68&#x02013;2.71&#x000a0;ppm, 3.07&#x02013;3.24&#x000a0;ppm, 3.59&#x02013;3.63&#x000a0;ppm) were excluded from the plasma bucket table.</p><p id="Par20">Urine 1D <sup>1</sup>H NOESY NMR spectra were segmented into buckets of 0.02&#x000a0;ppm width across the spectral region from 0.7 to 10.5&#x000a0;ppm, to reduce spectral complexity (due to the highly overlapping proton signals). The resonances of DSS (1.73&#x02013;1.79&#x000a0;ppm, 2.90&#x02013;2.93&#x000a0;ppm), urea (5.50&#x02013;6.24&#x000a0;ppm) and water (4.61&#x02013;5.16&#x000a0;ppm) were excluded from the urine bucket table as well.</p></sec><sec id="Sec9"><title>Statistical analysis and computational methods</title><p id="Par21">Metabolite identification was performed utilizing the free version of Chenomx NMR Suite 8.6, the databases Human Metabolome Database (HMDB), Biological Magnetic Resonance Bank (BMRB) and data from the literature (Wishart et al., <xref ref-type="bibr" rid="CR32">2007</xref>). Signals were assigned using both 1D and 2D NMR spectra, through examination of all the spectral characteristics such as chemical shifts (<italic>&#x003b4;</italic>), multiplicity and <italic>J</italic> coupling constants. Multivariate analysis (MVA) was the first step to statistically investigate biological data, discover possible outliers and classification trends. MVA was performed using the online available software MetaboAnalyst 5.0 (Pang et al., <xref ref-type="bibr" rid="CR21">2021</xref>). For plasma and serum samples the unsupervised method of Principle Component Analysis (PCA) and the supervised method of Partial Least Squares Discriminant Analysis (PLS-DA) were applied by performing Pareto scaling and normalization by median and range scaling, respectively. For urine samples, to overcome the differences in urine dilution, the application of normalization methods was also required. Probabilistic Quotient Normalization (PQN) and range scaling were chosen as methods for the best statistical preprocessing. The model was validated examining the parameters R<sup>2</sup> and Q<sup>2</sup> after a tenfold cross validation. The values of these parameters are characteristic for the model&#x02019;s fitness and predictability. Univariate statistical analysis was the key to analyze independently the non-overlapping metabolites&#x02019; peaks (Saccenti et al., <xref ref-type="bibr" rid="CR26">2014</xref>). This targeted analysis was conducted using the programming language R (R studio), via the non-parametric Kruskal-Wallis test. Metabolites with <italic>p</italic>-value &#x0003c;&#x02009;0.05 after the False Discovery Rate (FDR) correction were characterized as statistically significant. Correlation analysis between statistically significant metabolites and IGF-1 was performed using Pearson Correlation test and the statistical significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec id="Sec10"><title>Pathway analysis</title><p id="Par22">Metabolite Pathway analysis (MetPA) was performed by MetaboAnalyst 5.0, shedding light on the biological mechanisms and biochemical pathways which are involved and altered in GHD. The names of the statistically significant metabolites were imported as input, the hypergeometric test was chosen as enrichment method, the relative betweenness centrality was preferred for topological analysis while the Homo Sapiens was the selected pathway library from KEGG (Ren et al., <xref ref-type="bibr" rid="CR25">2015</xref>).</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Plasma metabolomic analysis</title><p id="Par23">For the needs of the current study, a total of eighty-five plasma samples (n&#x02009;=&#x02009;85) were screened: Forty-eight (n&#x02009;=&#x02009;48) samples from age-matched healthy controls (30 girls and 18 boys), twenty-two (n&#x02009;=&#x02009;22) samples from children diagnosed with GHD (10 girls and 12 boys), and fifteen (n&#x02009;=&#x02009;15) samples from children diagnosed with GHD three months after the initiation of GH therapy (6 girls and 9 boys). A total of 30 metabolites were detected and successfully assigned in plasma NMR spectra from GHD children (Table <xref rid="MOESM1" ref-type="media">S1</xref>).The CPMG NMR data resulted from the bucketing procedure were applied as input for the PCA (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>) and PLS-DA method, which provided a reliable model (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). The tenfold cross validation test demonstrated a Q<sup>2</sup> value of 0.20 and an R<sup>2</sup> value of 0.40 for the third latent variable. For the classification of plasma metabolic profiles among the three groups, the characteristic <italic>n</italic> methylene groups of fatty acids (1.28, 1.20, 1.24 and 0.88&#x000a0;ppm, &#x02013;(CH<sub>2</sub>)<sub>n</sub>&#x02013;), 3-hydroxybutyrate (1.20&#x000a0;ppm, &#x02013;CH<sub>3</sub>, d and 2.40, 2.28,&#x000a0;2.32&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, dd), glucose (3.72&#x000a0;ppm, &#x02013;CH&#x02013;, m) and lactate and threonine (1.36&#x000a0;ppm, &#x02013;CH<sub>3</sub>, d) were found to be statistically significant according to the VIP scores (VIP&#x02009;&#x0003e;&#x02009;1) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). Further validation of these results was achieved through univariate statistical analysis. Boxplots from the univariate analysis, representing the differentiation of the relative intensity among the three groups corroborated the results of MVA (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Specifically, the boxplots highlighted that the levels of the following seven metabolites, acetoacetate (2.28&#x000a0;ppm, &#x02013;CH<sub>3,</sub> s), acetone (2.24&#x000a0;ppm, &#x02013;CH<sub>3</sub>, s), 3-hydroxybutyrate (2.31&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, dd), 3-hydroxyisobutyrate (1.07&#x000a0;ppm, &#x02013;CH<sub>3,</sub> d), creatine (3.92&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, s) valine (1.04&#x000a0;ppm, &#x02013;CH<sub>3</sub>, d) and citrate (2.65&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, d) are increased in GHD children compared to healthy controls. These metabolites have been identified as statistically significant with <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05 after FDR correction (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Moreover, minor alterations were observed between the metabolic profiles of untreated and treated children over the three months of GH treatment.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Multivariate analysis of 1D <sup>1</sup>H CPMG plasma spectra obtained from children diagnosed with GHD before (yellow rhombus) and during the 3&#x000a0;months of GH replacement (green triangles) as compared with healthy controls (grey squares). <bold>a</bold> 2D PLS-DA scores plot indicates that the controls differ from GHD patients regardless of therapy. <bold>b</bold> Rank of the top ten variables identified by the PLS-DA according to the VIP scores on the x-axis. Colored boxes on the right correspond to the relative concetration of each specific variable in each group</p></caption><graphic xlink:href="11306_2024_2217_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Univariate statistical analysis (<bold>a&#x02013;g</bold>). Boxplots displaying the variation of relative concetration for each one of the seven plasma metabolites, which significantly differ between the three groups: healthy controls (grey, &#x0201c;control&#x0201d;), GHD children before the initiation of therapy (yellow, &#x0201c;ghd&#x0201d;) and GHD children after the 3&#x000a0;months of GH replacement (green, &#x0201c;therapy&#x0201d;)</p></caption><graphic xlink:href="11306_2024_2217_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Results of the univariate statistical analysis from plasma metabolites</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Metabolites</th><th align="left">3 groups</th><th align="left">Control-GHD</th><th align="left">Control-therapy</th><th align="left">Before-after therapy</th></tr><tr><th align="left"/><th align="left" colspan="4"><italic>p-value</italic></th></tr></thead><tbody><tr><td align="left">Acetoacetate</td><td align="left">0.011</td><td char="." align="char">0.010</td><td char="." align="char">0.122</td><td align="left">0.781</td></tr><tr><td align="left">Acetone</td><td align="left">0.005</td><td char="." align="char">0.030</td><td char="." align="char">0.007</td><td align="left">0.252</td></tr><tr><td align="left">3-Hydroxybutyrate</td><td align="left">0.005</td><td char="." align="char">0.028</td><td char="." align="char">0.008</td><td align="left">0.385</td></tr><tr><td align="left">3-Hydroxyisobutyrate</td><td align="left">0.001</td><td char="." align="char">0.011</td><td char="." align="char">7.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;5</sup></td><td align="left">0.45</td></tr><tr><td align="left">Creatine</td><td align="left">0.005</td><td char="." align="char">0.009</td><td char="." align="char">0.009</td><td align="left">1</td></tr><tr><td align="left">Valine</td><td align="left">0.018</td><td char="." align="char">0.066</td><td char="." align="char">0.030</td><td align="left">0.804</td></tr><tr><td align="left">Citrate</td><td align="left">0.005</td><td char="." align="char">0.11</td><td char="." align="char">0.002</td><td align="left">0.216</td></tr></tbody></table><table-wrap-foot><p>Seven statistically significant metabolites according to their <italic>p</italic>-values after the comparison between plasma samples obtained from healthy controls and GHD children before and during 3&#x000a0;months of GH replacement</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Serum metabolomic analysis</title><p id="Par24">In total, eighty-five serum samples (n&#x02009;=&#x02009;85) were screened: Forty-eight (n&#x02009;=&#x02009;48) samples from age-matched healthy controls (30 girls and 18 boys), twenty-two (n&#x02009;=&#x02009;22) samples from children diagnosed with GHD (10 girls and 12 boys), and fifteen (n&#x02009;=&#x02009;15) samples from children diagnosed with GHD three months after the initiation of GH therapy (6 girls and 9 boys). A total of 30 metabolites were successfully detected and assigned in serum NMR spectra from GHD children (Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). CPMG NMR data were explored via PCA (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>) and PLS-DA (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a), which evaluated with an R<sup>2</sup> of 0.59 and Q<sup>2</sup> of 0.41 for the third latent variable, after a tenfold cross validation test. The variables of importance for the PLS-DA classification of serum metabolic profiles indicate the <sup>1</sup>H peaks which correspond to the bucket 2.84 of the characteristic <italic>n</italic> methylene groups of fatty acids (&#x02013;(CH<sub>2</sub>)<sub>n</sub>&#x02013;), 3-hydroxybutyrate (1.20&#x000a0;ppm, &#x02013;CH<sub>3</sub>, d, 2.28 and 2.40&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, dd, and 4.24&#x000a0;ppm, &#x02013;CH&#x02013;, m), 3-hydroxyisobutyrate (1.12&#x000a0;ppm, &#x02013;CH<sub>3,</sub> d), citrate (2.64&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, d) and creatinine (4.04&#x000a0;ppm, &#x02013;CH<sub>2</sub>&#x02013;, s) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). Univariate analysis, in accordance with the results of the multivariate statistical approach, revealed higher levels of acetoacetate, acetone, 3 -hydroxybutyrate, 3-hydroxyisobutyrate, creatine and valine in GHD children (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), presenting a pattern of group differentiation similar to plasma <sup>1</sup>H NMR metabolic profile.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Multivariate analysis of 1D <sup>1</sup>H CPMG serum spectra obtained from children diagnosed with GHD before (yellow rhombus) and during 3&#x000a0;months of GH replacement (green triangles) as compared with healthy controls (grey squares). <bold>a</bold> 2D PLS-DA scores plot indicates that the controls differ from GHD patients regardless of therapy <bold>b</bold> Rank of the top ten variables identified by the PLS-DA according to the VIP scores on the x-axis. Colored boxes on the right correspond to the relative concetration of the specific metabolite in each group</p></caption><graphic xlink:href="11306_2024_2217_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Univariate statistical analysis (<bold>a&#x02013;f</bold>). Boxplots displaying the variation of relative concetration for each one of the six serum metabolites, which significantly differ between the three groups: healthy controls (grey, &#x0201c;control&#x0201d;), GHD children before the initiation of therapy (yellow, &#x0201c;ghd&#x0201d;) and GHD children after the 3&#x000a0;months of GH replacement (green, &#x0201c;therapy&#x0201d;)</p></caption><graphic xlink:href="11306_2024_2217_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Results of univariate statistical analysis of serum metabolites</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Metabolites</th><th align="left">3 groups</th><th align="left">Control-GHD</th><th align="left">Control-therapy</th><th align="left">Before-after therapy</th></tr><tr><th align="left"/><th align="left" colspan="4"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Acetoacetate</td><td align="left">0.048</td><td char="." align="char">0.05</td><td char="." align="char">0.12</td><td char="." align="char">0.86</td></tr><tr><td align="left">Acetone</td><td align="left">0.017</td><td char="." align="char">0.03</td><td char="." align="char">0.02</td><td char="." align="char">0.53</td></tr><tr><td align="left">3-Hydroxybutyrate</td><td align="left">1.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;4</sup></td><td char="." align="char">0.002</td><td char="." align="char">3.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;4</sup></td><td char="." align="char">0.41</td></tr><tr><td align="left">3-Hydroxyisobutyrate</td><td align="left">4.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;4</sup></td><td char="." align="char">0.006</td><td char="." align="char">6.0&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;4</sup></td><td char="." align="char">0.41</td></tr><tr><td align="left">Creatine</td><td align="left">0.019</td><td char="." align="char">0.017</td><td char="." align="char">0.07</td><td char="." align="char">0.56</td></tr><tr><td align="left">Valine</td><td align="left">0.041</td><td char="." align="char">0.11</td><td char="." align="char">0.04</td><td char="." align="char">0.37</td></tr></tbody></table><table-wrap-foot><p>Six statistically significant metabolites according to their <italic>p</italic>-values after the comparison between serum samples obtained from healthy controls and GHD children before and during 3&#x000a0;months of GH replacement</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Urine metabolomic analysis</title><p id="Par25">A total of 32 metabolites were successfully detected and assigned in the urine NMR spectra from GHD children (Table&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref>). Initial investigation of the urinary metabolic profiles performed via PCA analysis imprinted the increased heterogeneity of <sup>1</sup>H NMR spectra, leading to a low percentage (37.9% at the third principal component) of the model&#x02019;s explained cumulative variance (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Moreover, the PLS-DA model revealed low discrimination efficacy in classification of the three groups, with the tenfold cross validation test resulting in an R<sup>2</sup> value of 0.73 and Q<sup>2</sup> value of 0.24 for the third latent variable (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). The high dimensionality, which characterizes the urine metabolomic datasets, relative to the number of samples, often leads to overfitting models in statistical analysis. Due to the complex nature of urine as a biological fluid-varying in pH, metabolites, proteins, hormones, ions and other small molecular weight molecules and its highly variable composition both between individuals and within the same individual over time, only the metabolites with <sup>1</sup>H NMR discriminant signals were examined for statistical significance. Univariate statistical analysis of 17 metabolites (which did not present any overlapping features in <sup>1</sup>H NMR spectra) was performed. The relative concentrations of the metabolites were compared, yet none of them demonstrated statistical significance. To investigate alterations in metabolite levels a fold change analysis was conducted, revealing the relative differences between healthy controls and GHD children (comparison A). Additionally, comparisons between GHD children before and during 3&#x000a0;months of GH treatment (comparison B) as well as GHD children during 3&#x000a0;months of GH treatment and healthy controls (comparison C) were performed and are highlighted in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Multivariate analysis of 1D <sup>1</sup>H NOESY urine spectra obtained from children diagnosed with GHD before (yellow rhombus) and during 3&#x000a0;months of GH replacement (green triangles) as compared with healthy controls (grey squares). <bold>a</bold> 2D PCA scores plot with the first and second principal component <bold>b</bold> 2D PLS-DA scores plot indicate that the controls differ from GHD patients regardless of therapy</p></caption><graphic xlink:href="11306_2024_2217_Fig5_HTML" id="MO5"/></fig><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Fold change analysis of the 17 urine metabolic features detected among healthy controls and GHD children before and during 3&#x000a0;months of GH treatment</p></caption><graphic position="anchor" xlink:href="11306_2024_2217_Tab4_HTML" id="MO6"/></table-wrap></p></sec><sec id="Sec15"><title>Correlation analysis between potential biomarkers and IGF-1</title><p id="Par26">To investigate any correlation between the observed metabolites&#x02019; changes and the levels of IGF-1, Pearson&#x02019;s correlation analysis was conducted using the values of IGF-1 and the semiquantitative data of univariate analysis about the levels of the examined metabolites for each sample group, GHD children and GHD children 3&#x000a0;months after the initiation of treatment. The results are displayed in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>. Before GH therapy in children with GHD, serum levels of glutamine (r&#x02009;=&#x02009;0.66, <italic>p</italic>-value&#x02009;=&#x02009;0.0031) and glycine (r&#x02009;=&#x02009;0.53, <italic>p</italic>-value&#x02009;=&#x02009;0.024) were significant and positive correlated with IGF-1 (SDS), while urine levels of hippurate (r&#x02009;=&#x02009;&#x02212;&#x02009;0.58, <italic>p</italic>-value&#x02009;=&#x02009;0.0056) were significantly negatively correlated with IGF-1. After 3&#x000a0;months of GH treatment, only serum glutamine (r&#x02009;=&#x02009;0.58, <italic>p</italic>-value&#x02009;=&#x02009;0.0019) and serum pyruvate (r&#x02009;=&#x02009;&#x02212;&#x02009;0.49, <italic>p</italic>-value&#x02009;=&#x02009;0.011) showed statistically significant correlations with IGF-1 (SDS).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>2D Scatter plots (<bold>a&#x02013;e</bold>) with fit lines between different metabolites and IGF-1 (SDS). r: Spearman&#x02019;s rank correlation coefficient and the corresponding <italic>p</italic>-value is shown in each plot. <bold>a&#x02013;c</bold> Plots refer to serum glutamine, serum glycine and urine hippurate in correlation to IGF-1 (SDS) in GHD group while <bold>d, e</bold> plot shows glutamine and pyruvate changes in GHD group 3&#x000a0;months after initiation of therapy with GH in correlation to IGF-1</p></caption><graphic xlink:href="11306_2024_2217_Fig6_HTML" id="MO7"/></fig></p></sec><sec id="Sec16"><title>Metabolic disturbances induced by growth hormone deficiency</title><p id="Par27">Pathway analysis was the final approach on metabolomics data, aiming at the correlation of the up-regulated and down-regulated metabolites and the visualization of all the possibly affected metabolic processes. Semiquantitative data of all statistically significant plasma and serum metabolites were implemented into MetaboAnalyst pathway analysis. Plasma metabolome and serum metabolome view are displayed in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, b. Each circle corresponds to an altered metabolic pathway. Color intensity, from white to red reflects the increasing statistical significance, expressed via <italic>p</italic>-value (y-axis), while circle&#x02019;s diameter represents the pathway impact (x-axis). Furthermore, Tables&#x000a0;<xref rid="MOESM1" ref-type="media">S4</xref> and <xref rid="MOESM1" ref-type="media">S5</xref> show the detailed results about <italic>p</italic>-value with FDR correction and the impact values calculated from pathway topology analysis of plasma and serum metabolome, respectively.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Metabolic pathway analysis map of the GHD NMR plasma (<bold>a</bold>) and serum (<bold>b</bold>) metabolomic data</p></caption><graphic xlink:href="11306_2024_2217_Fig7_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par28">The aim of this study was to determine plasma, serum and urine metabolic profile of children diagnosed by GHD and investigate any effects of 3-months GH therapy on the metabolic signature through NMR spectroscopy. We further examined whether modifications on the levels of certain metabolites are correlated with changes in IGF-1 (SDS). Our findings revealed a distinct metabolic fingerprint in GHD children compared to healthy controls, but the alterations in the metabolome three months after initiation of GH therapy were minor, with no discriminative statistical power.</p><p id="Par29">More specifically, metabolites&#x02019; composition was similar either in plasma or in serum. Moreover, the results indicated increased levels of the following three ketone bodies acetoacetate, 3-hydroxyisobutyrate and 3-hydroxybutyrate. These findings suggest an upregulation of ketogenesis, this metabolic pathway that provides an alternative energy source when glucose is scarce. Ketogenesis is typically activated by counterregulatory hormones such as glucagon, growth hormone, and cortisol, which promote fatty acid mobilization for energy production (Kerner &#x00026; Hoppel, <xref ref-type="bibr" rid="CR16">2004</xref>). In the context of GHD the absence of this key regulator may lead to impaired glucose utilization and increased reliance on ketone body production to meet energy demands.</p><p id="Par30">The detailed analysis of the blood metabolome showed that children with GHD had higher circulating levels of valine compared to the control group. Interestingly, previous studies have confirmed lower levels of that metabolite in adults with acromegaly, a condition characterized by excessive GH secretion (Biagetti et al., <xref ref-type="bibr" rid="CR4">2019</xref>). This contrast supports the idea of a negative association between GH and the levels of valine.</p><p id="Par31">Moreover, we observed higher levels of creatine among children with GHD, suggesting a potential increase in skeletal mass protein turnover. This finding indicates that GHD may affect muscle metabolism, likely due to alterations in muscle protein synthesis and degradation.</p><p id="Par32">In contrast, plasma and serum glutamine levels were significantly reduced in children with GHD compared to healthy controls. This was supported also by univariate analysis, in where glutamine was assessed independently. GH therapy tended to normalize glutamine levels by increasing them, and, interestingly, these changes were statistically correlated with variations in IGF-1 SDS levels observed before and after initiation of treatment. Decreased glutamine levels have previously been found in a group of children with short stature, which included both GHD and idiopathic short stature cases (Xu et al., <xref ref-type="bibr" rid="CR33">2019</xref>).</p><p id="Par33">Furthermore, the NMR metabolomic analysis revealed that many of the metabolites altered in GHD could be classified as fatty acids (FAs). However, the methodology employed in this study focused to the aqueous metabolite content of the biological fluids analyzed. Moreover, this <sup>1</sup>H NMR analysis provides limited structural information about the presented lipids, which cannot lead to the specific lipid characterization. Recently, Yang et al. (<xref ref-type="bibr" rid="CR34">2023</xref>), published a detailed metabolic analysis focused on the lipid profile of adult GHD. Their identified signature markers include diacylglycerol (DG), cytidine diphosphate DG (CDP-DG), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol, phosphatidylserines, lysophosphatidylcholine, and lysophosphatidylethanolamine (LysoPE), all of which are implicated in pathways such as unsaturated fatty acids biosynthesis, sphingolipid metabolism, glycerophospholipid metabolism, fatty acid elongation, degradation and biosynthesis. Thus, based on our results we could only highlight a reduction in FAs in children with GHD, while GH treatment tented to normalize FAs levels, in accordance with the well-established lipolytic effect of GH (Molitch et al., <xref ref-type="bibr" rid="CR19">2011</xref>).</p><p id="Par34">Additionally, we identified all the other pathways involving metabolites with statistically significant levels. More specifically, for both plasma and serum metabolome the affected metabolic pathways included alanine, aspartate and glutamate metabolism, arginine and proline metabolism, butanoate metabolism, citrate cycle, cysteine and methionine metabolism, glyoxylate and dicarboxylate metabolism, glycine, serine and threonine metabolism, the pathway of glycolysis/gluconeogenesis, pantothenate and CoA biosynthesis, pyruvate metabolism, tyrosine metabolism as well as biosynthesis and degradation of valine, leucine and isoleucine.</p><p id="Par35">To evaluate the metabolomic signatures associated with different pediatric health conditions, we aimed to assess the similarities, differences and unique patterns within their respective NMR metabolic fingerprints. Consequently, we compared the results of the present study with the findings of the metabolomic analysis of children with premature adrenarche (PA), a previous research which was conducted using the same analytical approach and methodology (Matzarapi et al., <xref ref-type="bibr" rid="CR18">2022</xref>). More specifically, in PA children, plasma levels of alanine, glucose, glycerol, lactate, and leucine, as well as serum levels of glucose, glycerol, glycine, myo-inositol, and serine, were notably different. In contrast, the metabolomic signature associated with growth hormone deficiency (GHD) exhibited a high degree of similarity between plasma and serum samples, characterized by elevated concentrations of acetoacetate, acetone, 3-hydroxybutyrate, 3-hydroxyisobutyrate, creatine, and valine. Regarding the urinary metabolome, the GHD profile revealed differences in a panel of 17 metabolites, while the PA urinary metabolome highlighted four key metabolites: 3-methyl-histidine, hippurate, urocanic acid, and mannitol. Among these, only hippurate appears to be a common marker, showing reduced levels in both PA and GHD children compared to healthy individuals. Based on our observations, nuclear magnetic resonance (NMR) analysis of urinary metabolic profiles, even though it is complicated, has demonstrated enhanced sensitivity when applied to the classification of pediatric metabolic disorders through an untargeted analytical approach.</p><p id="Par36">As a constraint of this study regarding the interpretation of data could be considered the number of participants, which was relatively limited, particularly those who received GH treatment. A more extensive sample size could potentially improve the discrimination between pre and post GH treatment metabolomic profiles; however, the advantage of the paired samples empowers the statistical analysis concerning the differences between the levels of diverse metabolites across all fluids. Given that GH initiates its metabolic actions early, it is expected that the 3-month interval may be adequate to reveal changes. On the other hand, longitudinal data collected at longer intervals may reveal more significant or even different effects.</p><p id="Par37">Overall, it is undeniable that the analysis of the metabolome is quite complex and there have been limited studies to date regarding the GH deficiency, particularly in children. This study establishes a pivotal starting point, providing valuable insights into the relationship between the metabolic profile of children diagnosed with growth hormone deficiency (GHD) and those experiencing typical physiological growth. Additionally, it represents the first metabolome analysis aiming at correlating the impact of growth hormone (GH) therapy on children with GHD pre and post initiation of treatment. The identified IGF-1 associated metabolites can be investigated in future metabolomic analysis as potential biomarkers to monitor the metabolic effect of GH treatment. To reveal all the unique features of the metabolome and its role in the diagnosis and therapy of GHD more studies are required. Future studies should strive for increasing the sample size and examining the effects of GH replacement after six (6), twelve (12) and twenty-four (24) months (with a long term follow up outcomes up to 5&#x000a0;years or so). Moreover, as studies have demonstrated that GHD affects the pathway of biosynthesis of unsaturated fatty acids in adults, lipidomic analysis in pediatric population is also required to confirm these findings in younger ages and provide additional information about children&#x02019;s lipidomic profiles.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11306_2024_2217_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 556 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, D.C. and G.A.S; Methodology: D.C., A.G., A.E., E.A.A., P.D.G., S.A.C. and G.A.S.; Validation: D.C. and G.A.S.; Formal analysis: E.A.A. and P.D.G.; Investigation: E.A.A., A.G., A.E., P.D.G. and S.A.C.; Resources: D.C. and G.A.S.; Data curation: D.C., A.G., E.A.A., P.D.G., S.A.C., and G.A.S.; Writing-original draft preparation: E.A.A., A.G., P.D.G. and S.A.C.; Writing-review and editing: D.C. and G.A.S.; Visualization: S.A.C. and A.G.; Supervision: D.C. and G.A.S. All the authors have approved the submitted version and agree to be personally accountable for their own contributions and for ensuring that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and documented in the literature. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by HEAL-Link Greece. The work was supported by the INSPIRED (MIS 5002550) and OMIC-ENGINE (MIS 5002636), which are implemented under the Action &#x02018;Reinforcement of the Research and Innovation Infrastructure&#x02019;, funded by the Operational Program &#x02018;Competitiveness, Entrepreneurship, and Innovation&#x02019; (NSRF 2014&#x02013;2020) and co-financed by Greece and the European Union (European Regional Development Fund). Additionally, the EU FP7 REGPOT CT-2011-285950 &#x0201c;SEE-DRUG&#x0201d; project is acknowledged for the purchase of UPAT&#x02019;s 700MHz NMR equipment as well as EU HORIZONWIDERA-2022-TALENTS-01 ERA Chairs &#x0201c;ESPERANCE&#x0201d; program (Grant agreement ID: 101087215; 10.3030/101087215). The publication of the article in OA mode was financially supported by HEAL-Link.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par38">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par39">The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee of the University Hospital of Patras (protocol code: 106 and date of approval: 9/10/2020). Informed consent was obtained from the parents of all children involved in the study.</p></notes><notes id="FPar3"><title>Informed consent</title><p id="Par40">Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar-Oliveira</surname><given-names>MH</given-names></name><name><surname>Bartke</surname><given-names>A</given-names></name></person-group><article-title>Growth hormone deficiency: Health and longevity</article-title><source>Endocrine Reviews</source><year>2019</year><volume>40</volume><issue>2</issue><fpage>575</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1210/er.2018-00216</pub-id><pub-id pub-id-type="pmid">30576428</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Aguiar-Oliveira, M. H., &#x00026; Bartke, A. (2019). Growth hormone deficiency: Health and longevity. <italic>Endocrine Reviews,</italic><italic>40</italic>(2), 575&#x02013;601. 10.1210/er.2018-00216<pub-id pub-id-type="pmid">30576428</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Badaru</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>DM</given-names></name></person-group><article-title>Alternatives to growth hormone stimulation testing in children</article-title><source>Trends in Endocrinology and Metabolism</source><year>2004</year><volume>15</volume><issue>6</issue><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2004.06.004</pub-id><pub-id pub-id-type="pmid">15358277</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Badaru, A., &#x00026; Wilson, D. M. (2004). Alternatives to growth hormone stimulation testing in children. <italic>Trends in Endocrinology and Metabolism,</italic><italic>15</italic>(6), 252&#x02013;258. 10.1016/j.tem.2004.06.004<pub-id pub-id-type="pmid">15358277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernini</surname><given-names>P</given-names></name><name><surname>Bertini</surname><given-names>I</given-names></name><name><surname>Luchinat</surname><given-names>C</given-names></name><name><surname>Nincheri</surname><given-names>P</given-names></name><name><surname>Staderini</surname><given-names>S</given-names></name><name><surname>Turano</surname><given-names>P</given-names></name></person-group><article-title>Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks</article-title><source>Journal of Biomolecular NMR</source><year>2011</year><volume>49</volume><issue>3&#x02013;4</issue><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1007/s10858-011-9489-1</pub-id><pub-id pub-id-type="pmid">21380509</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bernini, P., Bertini, I., Luchinat, C., Nincheri, P., Staderini, S., &#x00026; Turano, P. (2011). Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. <italic>Journal of Biomolecular NMR,</italic><italic>49</italic>(3&#x02013;4), 231&#x02013;243. 10.1007/s10858-011-9489-1<pub-id pub-id-type="pmid">21380509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Biagetti</surname><given-names>B</given-names></name><name><surname>Herance</surname><given-names>JR</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name><name><surname>Aulinas</surname><given-names>A</given-names></name><name><surname>Palomino-Sch&#x000e4;tzlein</surname><given-names>M</given-names></name><name><surname>Mesa</surname><given-names>J</given-names></name><name><surname>Casta&#x000f1;o</surname><given-names>JP</given-names></name><name><surname>Luque</surname><given-names>RM</given-names></name><name><surname>Sim&#x000f3;</surname><given-names>R</given-names></name></person-group><article-title>Metabolic fingerprint of acromegaly and its potential usefulness in clinical practice</article-title><source>Journal of Clinical Medicine</source><year>2019</year><volume>8</volume><issue>10</issue><fpage>1549</fpage><pub-id pub-id-type="doi">10.3390/jcm8101549</pub-id><pub-id pub-id-type="pmid">31561638</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Biagetti, B., Herance, J. R., Ferrer, R., Aulinas, A., Palomino-Sch&#x000e4;tzlein, M., Mesa, J., Casta&#x000f1;o, J. P., Luque, R. M., &#x00026; Sim&#x000f3;, R. (2019). Metabolic fingerprint of acromegaly and its potential usefulness in clinical practice. <italic>Journal of Clinical Medicine,</italic><italic>8</italic>(10), 1549. 10.3390/jcm8101549<pub-id pub-id-type="pmid">31561638</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Bruzzone</surname><given-names>C</given-names></name><name><surname>Conde</surname><given-names>R</given-names></name><name><surname>Embade</surname><given-names>N</given-names></name><name><surname>Mato</surname><given-names>JM</given-names></name><name><surname>Millet</surname><given-names>O</given-names></name></person-group><article-title>Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19</article-title><source>Frontiers in Molecular Biosciences</source><year>2023</year><pub-id pub-id-type="doi">10.3389/fmolb.2023.1111482</pub-id><pub-id pub-id-type="pmid">36876049</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Bruzzone, C., Conde, R., Embade, N., Mato, J. M., &#x00026; Millet, O. (2023). Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19. <italic>Frontiers in Molecular Biosciences</italic>. 10.3389/fmolb.2023.1111482<pub-id pub-id-type="pmid">36876049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Caputo</surname><given-names>M</given-names></name><name><surname>Pigni</surname><given-names>S</given-names></name><name><surname>Agosti</surname><given-names>E</given-names></name><name><surname>Daffara</surname><given-names>T</given-names></name><name><surname>Ferrero</surname><given-names>A</given-names></name><name><surname>Filigheddu</surname><given-names>N</given-names></name><name><surname>Prodam</surname><given-names>F</given-names></name></person-group><article-title>Regulation of gh and gh signaling by nutrients</article-title><source>Cells</source><year>2021</year><pub-id pub-id-type="doi">10.3390/cells10061376</pub-id><pub-id pub-id-type="pmid">35011621</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Caputo, M., Pigni, S., Agosti, E., Daffara, T., Ferrero, A., Filigheddu, N., &#x00026; Prodam, F. (2021). Regulation of gh and gh signaling by nutrients. <italic>Cells</italic>. 10.3390/cells10061376<pub-id pub-id-type="pmid">35011621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Karagkouni</surname><given-names>E</given-names></name><name><surname>Kalavrizioti</surname><given-names>D</given-names></name><name><surname>Vamvakas</surname><given-names>S</given-names></name><name><surname>Zompra</surname><given-names>A</given-names></name><name><surname>Takis</surname><given-names>PG</given-names></name><name><surname>Goumenos</surname><given-names>DS</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name></person-group><article-title>NMR-Based metabolomics in differential diagnosis of chronic kidney disease (CKD) subtypes</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><issue>6</issue><fpage>490</fpage><pub-id pub-id-type="doi">10.3390/metabo12060490</pub-id><pub-id pub-id-type="pmid">35736423</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chasapi, S. A., Karagkouni, E., Kalavrizioti, D., Vamvakas, S., Zompra, A., Takis, P. G., Goumenos, D. S., &#x00026; Spyroulias, G. A. (2022). NMR-Based metabolomics in differential diagnosis of chronic kidney disease (CKD) subtypes. <italic>Metabolites,</italic><italic>12</italic>(6), 490. 10.3390/metabo12060490<pub-id pub-id-type="pmid">35736423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Christopoulou</surname><given-names>I</given-names></name><name><surname>Kostopoulou</surname><given-names>E</given-names></name><name><surname>Matzarapi</surname><given-names>K</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name><name><surname>Varvarigou</surname><given-names>A</given-names></name></person-group><article-title>Identification of novel biomarkers in late preterm neonates with respiratory distress syndrome (RDS) using urinary metabolomic analysis</article-title><source>Metabolites</source><year>2023</year><volume>13</volume><issue>5</issue><fpage>644</fpage><pub-id pub-id-type="doi">10.3390/metabo13050644</pub-id><pub-id pub-id-type="pmid">37233686</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Christopoulou, I., Kostopoulou, E., Matzarapi, K., Chasapi, S. A., Spyroulias, G. A., &#x00026; Varvarigou, A. (2023). Identification of novel biomarkers in late preterm neonates with respiratory distress syndrome (RDS) using urinary metabolomic analysis. <italic>Metabolites,</italic><italic>13</italic>(5), 644. 10.3390/metabo13050644<pub-id pub-id-type="pmid">37233686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Clish</surname><given-names>CB</given-names></name></person-group><article-title>Metabolomics: An emerging but powerful tool for precision medicine</article-title><source>Molecular Case Studies</source><year>2015</year><volume>1</volume><issue>1</issue><fpage>a000588</fpage><pub-id pub-id-type="doi">10.1101/mcs.a000588</pub-id><pub-id pub-id-type="pmid">27148576</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Clish, C. B. (2015). Metabolomics: An emerging but powerful tool for precision medicine. <italic>Molecular Case Studies,</italic><italic>1</italic>(1), a000588. 10.1101/mcs.a000588<pub-id pub-id-type="pmid">27148576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Dattani</surname><given-names>MT</given-names></name><name><surname>Malhotra</surname><given-names>N</given-names></name></person-group><article-title>A review of growth hormone deficiency</article-title><source>Paediatrics and Child Health</source><year>2019</year><volume>29</volume><issue>7</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.paed.2019.04.001</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dattani, M. T., &#x00026; Malhotra, N. (2019). A review of growth hormone deficiency. <italic>Paediatrics and Child Health</italic>, <italic>29</italic>(7), 285&#x02013;292. 10.1016/j.paed.2019.04.001</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Georgakopoulou</surname><given-names>I</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Bariamis</surname><given-names>SE</given-names></name><name><surname>Varvarigou</surname><given-names>A</given-names></name><name><surname>Spraul</surname><given-names>M</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name></person-group><article-title>Metabolic changes in early neonatal life: NMR analysis of the neonatal metabolic profile to monitor postnatal metabolic adaptations</article-title><source>Metabolomics</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11306-020-01680-4</pub-id><pub-id pub-id-type="pmid">32333120</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Georgakopoulou, I., Chasapi, S. A., Bariamis, S. E., Varvarigou, A., Spraul, M., &#x00026; Spyroulias, G. A. (2020). Metabolic changes in early neonatal life: NMR analysis of the neonatal metabolic profile to monitor postnatal metabolic adaptations. <italic>Metabolomics</italic>. 10.1007/s11306-020-01680-4<pub-id pub-id-type="pmid">32333120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiopoulou</surname><given-names>PD</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Christopoulou</surname><given-names>I</given-names></name><name><surname>Varvarigou</surname><given-names>A</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name></person-group><article-title>Untargeted 1H-NMR urine metabolomic analysis of preterm infants with neonatal sepsis</article-title><source>Applied Sciences (Switzerland)</source><year>2022</year><volume>12</volume><issue>4</issue><fpage>1932</fpage><pub-id pub-id-type="doi">10.3390/app12041932</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Georgiopoulou, P. D., Chasapi, S. A., Christopoulou, I., Varvarigou, A., &#x00026; Spyroulias, G. A. (2022). Untargeted 1H-NMR urine metabolomic analysis of preterm infants with neonatal sepsis. <italic>Applied Sciences (Switzerland),</italic><italic>12</italic>(4), 1932. 10.3390/app12041932</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Grimberg</surname><given-names>A</given-names></name><name><surname>DiVall</surname><given-names>SA</given-names></name><name><surname>Polychronakos</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>DB</given-names></name><name><surname>Cohen</surname><given-names>LE</given-names></name><name><surname>Quintos</surname><given-names>JB</given-names></name><name><surname>Rossi</surname><given-names>WC</given-names></name><name><surname>Feudtner</surname><given-names>C</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name></person-group><article-title>Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency</article-title><source>Hormone Research in Paediatrics</source><year>2017</year><volume>86</volume><issue>6</issue><fpage>361</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1159/000452150</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Grimberg, A., DiVall, S. A., Polychronakos, C., Allen, D. B., Cohen, L. E., Quintos, J. B., Rossi, W. C., Feudtner, C., &#x00026; Murad, M. H. (2017). Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. <italic>Hormone Research in Paediatrics,</italic><italic>86</italic>(6), 361&#x02013;397. 10.1159/000452150</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;ybye</surname><given-names>C</given-names></name><name><surname>Wahlstr&#x000f6;m</surname><given-names>E</given-names></name><name><surname>Tollet-Egnell</surname><given-names>P</given-names></name><name><surname>Norstedt</surname><given-names>G</given-names></name></person-group><article-title>Metabolomics: A tool for the diagnosis of GH deficiency and for monitoring GH replacement?</article-title><source>Endocrine Connections</source><year>2014</year><volume>3</volume><issue>4</issue><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1530/ec-14-0098</pub-id><pub-id pub-id-type="pmid">25312907</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">H&#x000f6;ybye, C., Wahlstr&#x000f6;m, E., Tollet-Egnell, P., &#x00026; Norstedt, G. (2014). Metabolomics: A tool for the diagnosis of GH deficiency and for monitoring GH replacement? <italic>Endocrine Connections,</italic><italic>3</italic>(4), 200&#x02013;206. 10.1530/ec-14-0098<pub-id pub-id-type="pmid">25312907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Katsila</surname><given-names>T</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Gomez Tamayo</surname><given-names>JC</given-names></name><name><surname>Chalikiopoulou</surname><given-names>C</given-names></name><name><surname>Siapi</surname><given-names>E</given-names></name><name><surname>Moros</surname><given-names>G</given-names></name><name><surname>Zoumpoulakis</surname><given-names>P</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name><name><surname>Kardamakis</surname><given-names>D</given-names></name></person-group><article-title>Three-dimensional cell metabolomics deciphers the anti-angiogenic properties of the radioprotectant amifostine</article-title><source>Cancers</source><year>2021</year><volume>13</volume><issue>12</issue><fpage>2877</fpage><pub-id pub-id-type="doi">10.3390/cancers13122877</pub-id><pub-id pub-id-type="pmid">34207535</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Katsila, T., Chasapi, S. A., Gomez Tamayo, J. C., Chalikiopoulou, C., Siapi, E., Moros, G., Zoumpoulakis, P., Spyroulias, G. A., &#x00026; Kardamakis, D. (2021). Three-dimensional cell metabolomics deciphers the anti-angiogenic properties of the radioprotectant amifostine. <italic>Cancers,</italic><italic>13</italic>(12), 2877. 10.3390/cancers13122877<pub-id pub-id-type="pmid">34207535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerner</surname><given-names>J</given-names></name><name><surname>Hoppel</surname><given-names>CL</given-names></name></person-group><article-title>Ketogenesis</article-title><source>Encyclopedia of Biological Chemistry</source><year>2004</year><volume>2</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/B0-12-443710-9/00346-X</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kerner, J., &#x00026; Hoppel, C. L. (2004). Ketogenesis. <italic>Encyclopedia of Biological Chemistry</italic>, <italic>2</italic>, 505&#x02013;507.</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Markley</surname><given-names>JL</given-names></name><name><surname>Br&#x000fc;schweiler</surname><given-names>R</given-names></name><name><surname>Edison</surname><given-names>AS</given-names></name><name><surname>Eghbalnia</surname><given-names>HR</given-names></name><name><surname>Powers</surname><given-names>R</given-names></name><name><surname>Raftery</surname><given-names>D</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><article-title>The future of NMR-based metabolomics</article-title><source>Current Opinion in Biotechnology</source><year>2017</year><volume>43</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2016.08.001</pub-id><pub-id pub-id-type="pmid">27580257</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Markley, J. L., Br&#x000fc;schweiler, R., Edison, A. S., Eghbalnia, H. R., Powers, R., Raftery, D., &#x00026; Wishart, D. S. (2017). The future of NMR-based metabolomics. <italic>Current Opinion in Biotechnology,</italic><italic>43</italic>, 34&#x02013;40. 10.1016/j.copbio.2016.08.001<pub-id pub-id-type="pmid">27580257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Matzarapi</surname><given-names>K</given-names></name><name><surname>Giannakopoulos</surname><given-names>A</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Kritikou</surname><given-names>D</given-names></name><name><surname>Efthymiadou</surname><given-names>A</given-names></name><name><surname>Chrysis</surname><given-names>D</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name></person-group><article-title>NMR-based metabolic profiling of children with premature adrenarche</article-title><source>Metabolomics</source><year>2022</year><pub-id pub-id-type="doi">10.1007/s11306-022-01941-4</pub-id><pub-id pub-id-type="pmid">36239863</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Matzarapi, K., Giannakopoulos, A., Chasapi, S. A., Kritikou, D., Efthymiadou, A., Chrysis, D., &#x00026; Spyroulias, G. A. (2022). NMR-based metabolic profiling of children with premature adrenarche. <italic>Metabolomics</italic>. 10.1007/s11306-022-01941-4<pub-id pub-id-type="pmid">36239863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Molitch</surname><given-names>ME</given-names></name><name><surname>Clemmons</surname><given-names>DR</given-names></name><name><surname>Malozowski</surname><given-names>S</given-names></name><name><surname>Merriam</surname><given-names>GR</given-names></name><name><surname>Vance</surname><given-names>ML</given-names></name></person-group><article-title>Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline</article-title><source>Journal of Clinical Endocrinology and Metabolism</source><year>2011</year><volume>96</volume><issue>6</issue><fpage>1587</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-0179</pub-id><pub-id pub-id-type="pmid">21602453</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., &#x00026; Vance, M. L. (2011). Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. <italic>Journal of Clinical Endocrinology and Metabolism,</italic><italic>96</italic>(6), 1587&#x02013;1609. 10.1210/jc.2011-0179<pub-id pub-id-type="pmid">21602453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Neinast</surname><given-names>M</given-names></name><name><surname>Murashige</surname><given-names>D</given-names></name><name><surname>Arany</surname><given-names>Z</given-names></name></person-group><article-title>Branched chain amino acids</article-title><source>Annual Review of Physiology</source><year>2018</year><volume>26</volume><fpage>139</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-020518</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Neinast, M., Murashige, D., &#x00026; Arany, Z. (2018). Branched chain amino acids. <italic>Annual Review of Physiology,</italic><italic>26</italic>, 139&#x02013;164. 10.1146/annurev-physiol-020518</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>De Lima Morais</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Barrette</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>C</given-names></name><name><surname>Jacques</surname><given-names>P&#x000c9;</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><article-title>MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights</article-title><source>Nucleic Acids Research</source><year>2021</year><volume>49</volume><issue>W1</issue><fpage>W388</fpage><lpage>W396</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab382</pub-id><pub-id pub-id-type="pmid">34019663</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Pang, Z., Chong, J., Zhou, G., De Lima Morais, D. A., Chang, L., Barrette, M., Gauthier, C., Jacques, P. &#x000c9;., Li, S., &#x00026; Xia, J. (2021). MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. <italic>Nucleic Acids Research,</italic><italic>49</italic>(W1), W388&#x02013;W396. 10.1093/nar/gkab382<pub-id pub-id-type="pmid">34019663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>JTM</given-names></name><name><surname>Athersuch</surname><given-names>TJ</given-names></name><name><surname>Ebbels</surname><given-names>TMD</given-names></name><name><surname>Lindon</surname><given-names>JC</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name><name><surname>Keun</surname><given-names>HC</given-names></name></person-group><article-title>Robust algorithms for automated chemical shift calibration of 1D 1H NMR spectra of blood serum</article-title><source>Analytical Chemistry</source><year>2008</year><volume>80</volume><issue>18</issue><fpage>7158</fpage><lpage>7162</lpage><pub-id pub-id-type="doi">10.1021/ac8011494</pub-id><pub-id pub-id-type="pmid">18702533</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Pearce, J. T. M., Athersuch, T. J., Ebbels, T. M. D., Lindon, J. C., Nicholson, J. K., &#x00026; Keun, H. C. (2008). Robust algorithms for automated chemical shift calibration of 1D 1H NMR spectra of blood serum. <italic>Analytical Chemistry,</italic><italic>80</italic>(18), 7158&#x02013;7162. 10.1021/ac8011494<pub-id pub-id-type="pmid">18702533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Preter</surname><given-names>VD</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name></person-group><article-title>Metabolomics as a diagnostic tool in gastroenterology</article-title><source>World Journal of Gastrointestinal Pharmacology and Therapeutics</source><year>2013</year><volume>4</volume><issue>4</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.4292/wjgpt.v4.i4.97</pub-id><pub-id pub-id-type="pmid">24199025</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Preter, V. D., &#x00026; Verbeke, K. (2013). Metabolomics as a diagnostic tool in gastroenterology. <italic>World Journal of Gastrointestinal Pharmacology and Therapeutics,</italic><italic>4</italic>(4), 97. 10.4292/wjgpt.v4.i4.97<pub-id pub-id-type="pmid">24199025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Puchades-Carrasco</surname><given-names>L</given-names></name><name><surname>Palomino-Sch&#x000e4;tzlein</surname><given-names>M</given-names></name><name><surname>P&#x000e9;rez-Rambla</surname><given-names>C</given-names></name><name><surname>Pineda-Lucena</surname><given-names>A</given-names></name></person-group><article-title>Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers</article-title><source>Briefings in Bioinformatics</source><year>2016</year><volume>17</volume><issue>3</issue><fpage>541</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1093/bib/bbv077</pub-id><pub-id pub-id-type="pmid">26342127</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Puchades-Carrasco, L., Palomino-Sch&#x000e4;tzlein, M., P&#x000e9;rez-Rambla, C., &#x00026; Pineda-Lucena, A. (2016). Bioinformatics tools for the analysis of NMR metabolomics studies focused on the identification of clinically relevant biomarkers. <italic>Briefings in Bioinformatics,</italic><italic>17</italic>(3), 541&#x02013;552. 10.1093/bib/bbv077<pub-id pub-id-type="pmid">26342127</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Hinzman</surname><given-names>AA</given-names></name><name><surname>Kang</surname><given-names>EL</given-names></name><name><surname>Szczesniak</surname><given-names>RD</given-names></name><name><surname>Lu</surname><given-names>LJ</given-names></name></person-group><article-title>Computational and statistical analysis of metabolomics data</article-title><source>Metabolomics</source><year>2015</year><volume>11</volume><issue>6</issue><fpage>1492</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1007/s11306-015-0823-6</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ren, S., Hinzman, A. A., Kang, E. L., Szczesniak, R. D., &#x00026; Lu, L. J. (2015). Computational and statistical analysis of metabolomics data. <italic>Metabolomics,</italic><italic>11</italic>(6), 1492&#x02013;1513. 10.1007/s11306-015-0823-6</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Saccenti</surname><given-names>E</given-names></name><name><surname>Hoefsloot</surname><given-names>HCJ</given-names></name><name><surname>Smilde</surname><given-names>AK</given-names></name><name><surname>Westerhuis</surname><given-names>JA</given-names></name><name><surname>Hendriks</surname><given-names>MMWB</given-names></name></person-group><article-title>Reflections on univariate and multivariate analysis of metabolomics data</article-title><source>Metabolomics</source><year>2014</year><volume>10</volume><issue>3</issue><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1007/s11306-013-0598-6</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Saccenti, E., Hoefsloot, H. C. J., Smilde, A. K., Westerhuis, J. A., &#x00026; Hendriks, M. M. W. B. (2014). Reflections on univariate and multivariate analysis of metabolomics data. <italic>Metabolomics,</italic><italic>10</italic>(3), 361&#x02013;374. 10.1007/s11306-013-0598-6</mixed-citation></citation-alternatives></ref><ref id="CR27"><mixed-citation publication-type="other">Society, R. (2000). <italic>CONSENSUS Consensus Guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH</italic>. <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/jcem/article/85/11/3990/2852253">https://academic.oup.com/jcem/article/85/11/3990/2852253</ext-link></mixed-citation></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez-Diez</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>J</given-names></name><name><surname>Adamski</surname><given-names>J</given-names></name><name><surname>Chasapi</surname><given-names>SA</given-names></name><name><surname>Luchinat</surname><given-names>C</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><name><surname>Santucci</surname><given-names>C</given-names></name><name><surname>Spyridonidis</surname><given-names>A</given-names></name><name><surname>Spyroulias</surname><given-names>GA</given-names></name><name><surname>Tenori</surname><given-names>L</given-names></name><name><surname>Wang-Sattler</surname><given-names>R</given-names></name><name><surname>Saccenti</surname><given-names>E</given-names></name></person-group><article-title>Plasma and Serum Metabolite Association Networks: Comparability within and between studies using NMR and MS profiling</article-title><source>Journal of Proteome Research</source><year>2017</year><volume>16</volume><issue>7</issue><fpage>2547</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.7b00106</pub-id><pub-id pub-id-type="pmid">28517934</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Suarez-Diez, M., Adam, J., Adamski, J., Chasapi, S. A., Luchinat, C., Peters, A., Prehn, C., Santucci, C., Spyridonidis, A., Spyroulias, G. A., Tenori, L., Wang-Sattler, R., &#x00026; Saccenti, E. (2017). Plasma and Serum Metabolite Association Networks: Comparability within and between studies using NMR and MS profiling. <italic>Journal of Proteome Research,</italic><italic>16</italic>(7), 2547&#x02013;2559. 10.1021/acs.jproteome.7b00106<pub-id pub-id-type="pmid">28517934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Th&#x000e9;venot</surname><given-names>EA</given-names></name><name><surname>Roux</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ezan</surname><given-names>E</given-names></name><name><surname>Junot</surname><given-names>C</given-names></name></person-group><article-title>Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses</article-title><source>Journal of Proteome Research</source><year>2015</year><volume>14</volume><issue>8</issue><fpage>3322</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00354</pub-id><pub-id pub-id-type="pmid">26088811</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Th&#x000e9;venot, E. A., Roux, A., Xu, Y., Ezan, E., &#x00026; Junot, C. (2015). Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. <italic>Journal of Proteome Research,</italic><italic>14</italic>(8), 3322&#x02013;3335. 10.1021/acs.jproteome.5b00354<pub-id pub-id-type="pmid">26088811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><mixed-citation publication-type="other">Vignoli, A., Meoni, G., Ghini, V., Di Cesare, F., Tenori, L., Luchinat, C., &#x00026; Turano, P. (2022). NMR-Based metabolomics to evaluate individual response to treatments.10.1007/164_2022_618</mixed-citation></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Melnikov</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tritos</surname><given-names>NA</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>High-performance liquid chromatography-mass spectrometry-based lipid metabolite profiling of acromegaly</article-title><source>Journal of Clinical Endocrinology and Metabolism</source><year>2020</year><volume>105</volume><issue>4</issue><fpage>E1075</fpage><lpage>E1084</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa014</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang, M., Guo, S., He, M., Shao, X., Feng, L., Yu, Y., Gong, W., Liu, Q., Melnikov, V., Wang, X., He, Z., Jiang, L., Chen, M., Sun, J., Cai, J., Zhao, Y., Li, Y., Tritos, N. A., Hu, Z., &#x00026; Zhang, Z. (2020). High-performance liquid chromatography-mass spectrometry-based lipid metabolite profiling of acromegaly. <italic>Journal of Clinical Endocrinology and Metabolism,</italic><italic>105</italic>(4), E1075&#x02013;E1084. 10.1210/clinem/dgaa014</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Tzur</surname><given-names>D</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Eisner</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Jewell</surname><given-names>K</given-names></name><name><surname>Arndt</surname><given-names>D</given-names></name><name><surname>Sawhney</surname><given-names>S</given-names></name><name><surname>Fung</surname><given-names>C</given-names></name><name><surname>Nikolai</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>M</given-names></name><name><surname>Coutouly</surname><given-names>MA</given-names></name><name><surname>Forsythe</surname><given-names>I</given-names></name><name><surname>Tang</surname><given-names>P</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Jeroncic</surname><given-names>K</given-names></name><name><surname>Stothard</surname><given-names>P</given-names></name><name><surname>Amegbey</surname><given-names>G</given-names></name><name><surname>Block</surname><given-names>D</given-names></name><name><surname>Hau</surname><given-names>DD</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Miniaci</surname><given-names>J</given-names></name><name><surname>Clements</surname><given-names>M</given-names></name><name><surname>Gebremedhin</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Duggan</surname><given-names>GE</given-names></name><name><surname>MacInnis</surname><given-names>GD</given-names></name><name><surname>Weljie</surname><given-names>AM</given-names></name><name><surname>Dowlatabadi</surname><given-names>R</given-names></name><name><surname>Bamforth</surname><given-names>F</given-names></name><name><surname>Clive</surname><given-names>D</given-names></name><name><surname>Greiner</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Marrie</surname><given-names>T</given-names></name><name><surname>Sykes</surname><given-names>BD</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Querengesser</surname><given-names>L</given-names></name></person-group><article-title>HMDB: The human metabolome database</article-title><source>Nucleic Acids Research</source><year>2007</year><pub-id pub-id-type="doi">10.1093/nar/gkl923</pub-id><pub-id pub-id-type="pmid">18048412</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., Fung, C., Nikolai, L., Lewis, M., Coutouly, M. A., Forsythe, I., Tang, P., Shrivastava, S., Jeroncic, K., Stothard, P., &#x02026; Querengesser, L. (2007). HMDB: The human metabolome database. <italic>Nucleic Acids Research</italic>. 10.1093/nar/gkl923<pub-id pub-id-type="pmid">18048412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name></person-group><article-title>Metabolomic analysis reveals metabolic characteristics of children with short stature caused by growth hormone deficiency</article-title><source>Clinical Science</source><year>2019</year><volume>133</volume><issue>6</issue><fpage>777</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1042/CS20181005</pub-id><pub-id pub-id-type="pmid">30867230</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Xu, R., Zhu, H., Zhang, C., Shen, G., &#x00026; Feng, J. (2019). Metabolomic analysis reveals metabolic characteristics of children with short stature caused by growth hormone deficiency. <italic>Clinical Science,</italic><italic>133</italic>(6), 777&#x02013;788. 10.1042/CS20181005<pub-id pub-id-type="pmid">30867230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name></person-group><article-title>High-performance liquid chromatography-mass spectrometry&#x02013;based metabolic profiling of adult growth hormone deficiency</article-title><source>The Journal of Clinical Endocrinology &#x00026; Metabolism</source><year>2023</year><pub-id pub-id-type="doi">10.1210/clinem/dgad129</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yang, H., Chen, M., Wang, Y., Jiang, L., Wang, L., Duan, L., Gong, F., Zhu, H., &#x00026; Pan, H. (2023). High-performance liquid chromatography-mass spectrometry&#x02013;based metabolic profiling of adult growth hormone deficiency. <italic>The Journal of Clinical Endocrinology &#x00026; Metabolism</italic>. 10.1210/clinem/dgad129</mixed-citation></citation-alternatives></ref></ref-list></back></article>